CSL wins $230 million H1N1 vaccine order
Monday, 01 June, 2009
CSL's US subsidiary, CSL Biotherapies, has signed a $230 million (USD180 million) contract with the US Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine in bulk form.
CSL has also announced it will supply the Novel A (H1N1) vaccine to Australia.
The vaccine will be manufacturered at CSL's facility in Parkville, Victoria, and will support the HHS pre-pandemic influenza preparation efforts.
The new vccine will be tested in clinical trials funded by HHS.
CSL has declared that it will maintain its committment to supply seasonal influenza vaccines to Australia, the US and other markets.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
